Identification

Name
Docetaxel
Accession Number
DB01248  (APRD00932)
Type
Small Molecule
Groups
Approved, Investigational
Description

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.

Structure
Thumb
Synonyms
  • Docetaxel anhydrous
  • N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
  • N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
  • TXL
External IDs
CKD-810 / RP-6976
Product Ingredients
IngredientUNIICASInChI Key
Docetaxel trihydrate15H5577CQD148408-66-6XCDIRYDKECHIPE-QHEQPUDQSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DocefrezKitSun Pharma Global FZE2011-05-032017-02-03Us
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousAccord Healthcare Limited2013-05-15Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/2mLIntravenousPfizer Laboratories Div Pfizer Inc.2014-06-232017-08-31Us
DocetaxelInjection, solution10 mg/mLIntravenousHospira, Inc.2011-03-08Not applicableUs
DocetaxelInjection, solution, concentrate160 mg/8mLIntravenousWinthrop U.S.2016-10-23Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousNorth Star Rx Llc2016-01-01Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2016-06-282017-11-09Us
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma Company2014-09-01Not applicableUs
DocetaxelKitAccord Healthcare Limited2011-06-30Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DocetaxelInjection, solution10 mg/mLIntravenousIngenus Pharmaceuticals Llc2017-09-07Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousDr Reddy's Laboratories2014-11-10Not applicableUs
DocetaxelInjection, solution80 mg/4mLIntravenousDr Reddy's Laboratories2017-08-22Not applicableUs
DocetaxelSolution20 mg/mLIntravenousSagent Pharmaceuticals2013-07-012017-03-31Us
DocetaxelInjection, solution, concentrate80 mg/4mLIntravenousTeva Parenteral Medicines, Inc.2015-12-31Not applicableUs
DocetaxelInjection, solution10 mg/mLIntravenousIngenus Pharmaceuticals Llc2017-09-07Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousX Gen Pharmaceuticals, Inc.2017-04-17Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousDr Reddy's Laboratories2014-11-10Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousDr Reddy's Laboratories2017-08-22Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousSagent Pharmaceuticals2017-09-15Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Docetaxel MylanInjection, solution, concentrate20 mg/1mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate200 mg/10mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate80 mg/4mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate200 mg/10mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate20 mg/1mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate80 mg/4mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel Teva PharmaInjection, solution, concentrate20 mgIntravenousTeva Pharma B.V.2011-01-21Not applicableEu
Docetaxel Teva PharmaInjection, solution, concentrate80 mgIntravenousTeva Pharma B.V.2011-01-21Not applicableEu
Categories
UNII
699121PHCA
CAS number
114977-28-5
Weight
Average: 807.8792
Monoisotopic: 807.346605409
Chemical Formula
C43H53NO14
InChI Key
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][[email protected]@]12C[[email protected]](O)[[email protected]@]3(C)C(=O)[[email protected]](O)C4=C(C)[[email protected]](C[[email protected]@](O)([[email protected]@H](OC(=O)C5=CC=CC=C5)[[email protected]]3([H])[[email protected]@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[[email protected]](O)[[email protected]@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.

Structured Indications
Pharmacodynamics

Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Mechanism of action

Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

TargetActionsOrganism
ATubulin beta-1 chainNot AvailableHuman
UApoptosis regulator Bcl-2Not AvailableHuman
AMicrotubule-associated protein 2Not AvailableHuman
AMicrotubule-associated protein 4Not AvailableHuman
AMicrotubule-associated protein tauNot AvailableHuman
UNuclear receptor subfamily 1 group I member 2
binder
Human
Absorption

The pharmacokinetic profile is consistent with a three-compartment model. The area under the curve (AUC) was dose proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours.

Volume of distribution

The initial rapid decline represents distribution to the peripheral compartments and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral compartment. * 113 L

Protein binding

In vitro studies show that 94% protein bound, mainly to a1-acid glycoprotein, albumin, and lipoproteins. When measured in cancer patients, docetaxel is 97% bound to plasma protein. Dexamethasone does not affect the protein binding of docetaxel.

Metabolism

Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites).

Route of elimination

Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively.

Half life

Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.

Clearance
  • 21 L/h/m2 [Total body clearance, cancer patients after IV administration of 20–115 mg/m2]
Toxicity

Oral LD50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Docetaxel Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Canalicular multispecific organic anion transporter 1---(G;G) / (C;G)G AlleleADR Directly StudiedPatients with this polymorphism in ABCC2 are at a higher risk of experiencing drug-induced leukopenia and drug-induced neutropenia when treated with docetaxel.Details

Interactions

Drug Interactions
DrugInteractionDrug group
10-hydroxycamptothecinThe risk or severity of adverse effects can be increased when Docetaxel is combined with 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Docetaxel can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Docetaxel can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyestradiol.Investigational
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3,3'-diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3,4-Dihydroxybenzoic Acid.Experimental
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 6-O-benzylguanine.Investigational
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 8-azaguanine.Experimental
9-aminocamptothecinThe risk or severity of adverse effects can be increased when Docetaxel is combined with 9-aminocamptothecin.Investigational
AbirateroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Abiraterone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Docetaxel.Experimental
AclarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aclarubicin.Investigational
Acridine CarboxamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Acridine Carboxamide.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.Investigational
AfatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afatinib.Approved
AfimoxifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afimoxifene.Investigational
AfliberceptThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aflibercept.Approved
AlatrofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alatrofloxacin.Withdrawn
AlbendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.Approved
AlectinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alemtuzumab.Approved, Investigational
AlitretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alitretinoin.Approved, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Altretamine.Approved
AlvocidibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alvocidib.Experimental, Investigational
AminoglutethimideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminoglutethimide.Approved, Investigational
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminolevulinic acid.Approved
AmiodaroneThe metabolism of Docetaxel can be decreased when combined with Amiodarone.Approved, Investigational
AmonafideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amonafide.Investigational
AmorolfineThe metabolism of Docetaxel can be decreased when combined with Amorolfine.Approved, Investigational
Amphotericin BThe metabolism of Docetaxel can be decreased when combined with Amphotericin B.Approved, Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amrubicin.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amsacrine.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anagrelide.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anastrozole.Approved, Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anecortave.Investigational
AnidulafunginThe metabolism of Docetaxel can be decreased when combined with Anidulafungin.Approved, Investigational
annamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with annamycin.Investigational
AP 12009The risk or severity of adverse effects can be increased when Docetaxel is combined with AP 12009.Investigational
AP24534The risk or severity of adverse effects can be increased when Docetaxel is combined with AP24534.Investigational
ApaziquoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Apaziquone.Investigational
AprepitantThe serum concentration of Docetaxel can be increased when it is combined with Aprepitant.Approved, Investigational
Arotinoid acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arotinoid acid.Experimental
Arsanilic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Docetaxel can be decreased when combined with Artemether.Approved
AsparaginaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Asparaginase.Approved
AtazanavirThe metabolism of Docetaxel can be decreased when combined with Atazanavir.Approved, Investigational
AtezolizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Atezolizumab.Approved
AtomoxetineThe metabolism of Docetaxel can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Atorvastatin.Approved
AxitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Axitinib.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azathioprine.Approved
Azelaic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azelaic Acid.Approved
Bafilomycin A1The metabolism of Docetaxel can be decreased when combined with Bafilomycin A1.Experimental
BatimastatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Batimastat.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Docetaxel.Investigational
BelinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Belinostat.Approved, Investigational
BelotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Belotecan.Investigational
BendamustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bendamustine.Approved, Investigational
Benzoic AcidThe metabolism of Docetaxel can be decreased when combined with Benzoic Acid.Approved
BesifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Besifloxacin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bexarotene.Approved, Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bicalutamide.Approved
BifonazoleThe metabolism of Docetaxel can be decreased when combined with Bifonazole.Approved, Investigational
BinetrakinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Binetrakin.Investigational
BizelesinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bizelesin.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Blinatumomab.Approved
BoceprevirThe metabolism of Docetaxel can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Docetaxel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bosutinib.Approved
Brefeldin AThe metabolism of Docetaxel can be decreased when combined with Brefeldin A.Experimental
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Brentuximab vedotin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Docetaxel.Approved, Investigational
BroxuridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Broxuridine.Investigational
Bryostatin 1The risk or severity of adverse effects can be increased when Docetaxel is combined with Bryostatin 1.Investigational
BSI-201The risk or severity of adverse effects can be increased when Docetaxel is combined with BSI-201.Investigational
BuserelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Buserelin.Approved
BusulfanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Busulfan.Approved, Investigational
ButenafineThe metabolism of Docetaxel can be decreased when combined with Butenafine.Approved
Buthionine SulfoximineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Buthionine Sulfoximine.Investigational
ButoconazoleThe metabolism of Docetaxel can be decreased when combined with Butoconazole.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabergoline.Approved
CabozantinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabozantinib.Approved
CalcipotriolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Calcipotriol.Approved
CamptothecinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Camptothecin.Experimental
CandicidinThe metabolism of Docetaxel can be decreased when combined with Candicidin.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Canertinib.Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Capecitabine.Approved, Investigational
Capric acidThe metabolism of Docetaxel can be decreased when combined with Capric acid.Experimental
CarbamazepineThe metabolism of Docetaxel can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinCarboplatin may increase the myelosuppressive activities of Docetaxel.Approved
CarboquoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carboquone.Experimental
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carboxyamidotriazole.Investigational
CarfilzomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carfilzomib.Approved
CarmofurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmofur.Withdrawn
CarmustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmustine.Approved
CaspofunginThe metabolism of Docetaxel can be decreased when combined with Caspofungin.Approved
CatumaxomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Catumaxomab.Approved, Investigational
CediranibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cediranib.Investigational
CeritinibThe serum concentration of Docetaxel can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Docetaxel.Withdrawn
CeruleninThe metabolism of Docetaxel can be decreased when combined with Cerulenin.Approved
CetuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorambucil.Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorotrianisene.Investigational, Withdrawn
ChloroxineThe metabolism of Docetaxel can be decreased when combined with Chloroxine.Approved
CholesterolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cholesterol.Experimental, Investigational
CiclopiroxThe metabolism of Docetaxel can be decreased when combined with Ciclopirox.Approved, Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the myelosuppressive activities of Docetaxel.Approved
CladribineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Docetaxel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Docetaxel can be decreased when combined with Clemastine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clofarabine.Approved, Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Docetaxel.Approved
ClotrimazoleThe metabolism of Docetaxel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clozapine.Approved
CobicistatThe metabolism of Docetaxel can be decreased when combined with Cobicistat.Approved
CobimetinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cobimetinib.Approved
ColchicineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Colchicine.Approved
CombretastatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Combretastatin.Investigational
ConivaptanThe serum concentration of Docetaxel can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe metabolism of Docetaxel can be decreased when combined with Cordycepin.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Docetaxel.Approved
Coumermycin A1The risk or severity of adverse effects can be increased when Docetaxel is combined with Coumermycin A1.Experimental
CrenolanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Crenolanib.Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Docetaxel is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
CyclosporineThe metabolism of Docetaxel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Docetaxel.Experimental
Cyproterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine.Approved, Investigational
DabrafenibThe serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dacarbazine.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dactinomycin.Approved
DaratumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daratumumab.Approved
DarunavirThe metabolism of Docetaxel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Docetaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daunorubicin.Approved
DecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Docetaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of adverse effects can be increased when Docetaxel is combined with Degarelix.Approved
DelavirdineThe metabolism of Docetaxel can be decreased when combined with Delavirdine.Approved
DemecolcineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Demecolcine.Experimental
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Docetaxel.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Deoxyspergualin.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Docetaxel.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dianhydrogalactitol.Investigational
DichloropheneThe metabolism of Docetaxel can be decreased when combined with Dichlorophene.Vet Approved
DidoxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Didox.Investigational
DienogestThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dienogest.Approved
diethylnorspermineThe risk or severity of adverse effects can be increased when Docetaxel is combined with diethylnorspermine.Investigational
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Docetaxel.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Docetaxel.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Docetaxel.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Docetaxel.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Docetaxel.Experimental
DihydroergotamineThe metabolism of Docetaxel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Docetaxel can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.Approved
Dolastatin 10The risk or severity of adverse effects can be increased when Docetaxel is combined with Dolastatin 10.Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxifluridine.Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Docetaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Docetaxel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Docetaxel can be increased when it is combined with Dronedarone.Approved
DuligotuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Duligotuzumab.Investigational
EcabetThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ecabet.Approved, Investigational
EconazoleThe metabolism of Docetaxel can be decreased when combined with Econazole.Approved
EdrecolomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Edrecolomab.Experimental, Investigational
EfaproxiralThe risk or severity of adverse effects can be increased when Docetaxel is combined with Efaproxiral.Investigational
EfatutazoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Efatutazone.Investigational
EfinaconazoleThe metabolism of Docetaxel can be decreased when combined with Efinaconazole.Approved
EflornithineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eflornithine.Approved, Withdrawn
EG009The risk or severity of adverse effects can be increased when Docetaxel is combined with EG009.Investigational
ElotuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Elotuzumab.Approved
ElsamitrucinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Elsamitrucin.Investigational
EltrombopagThe serum concentration of Docetaxel can be increased when it is combined with Eltrombopag.Approved
EndostatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Endostatin.Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enoxacin.Approved, Investigational
EnrofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enrofloxacin.Vet Approved
EntinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Docetaxel can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epigallocatechin Gallate.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epirubicin.Approved
EpofolateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epofolate.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Docetaxel.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Docetaxel.Approved
EribulinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Docetaxel can be decreased when combined with Erythromycin.Approved, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Estramustine.Approved
EtanidazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etanidazole.Investigational
Ethiodized oilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethiodized oil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate.Withdrawn
EtoglucidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etoglucid.Experimental
EtoposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etoposide.Approved
EverolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Everolimus.Approved
ExatecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exatecan.Investigational
ExemestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exemestane.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Docetaxel is combined with exisulind.Investigational
FenretinideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fenretinide.Investigational
FenticonazoleThe metabolism of Docetaxel can be decreased when combined with Fenticonazole.Experimental
FiacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fiacitabine.Investigational
FingolimodDocetaxel may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fleroxacin.Approved
FloxuridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Floxuridine.Approved
FluconazoleThe metabolism of Docetaxel can be decreased when combined with Fluconazole.Approved
FlucytosineThe metabolism of Docetaxel can be decreased when combined with Flucytosine.Approved
FludarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fludarabine.Approved
FlumequineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flumequine.Withdrawn
FluorouracilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fluorouracil.Approved
FlutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flutamide.Approved
FlutrimazoleThe metabolism of Docetaxel can be decreased when combined with Flutrimazole.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Docetaxel.Approved
FluvoxamineThe metabolism of Docetaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formestane.Approved, Investigational, Withdrawn
FormycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formycin.Experimental
FosamprenavirThe metabolism of Docetaxel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Docetaxel can be increased when it is combined with Fosaprepitant.Approved
FosbretabulinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fosbretabulin.Investigational
FosphenytoinThe metabolism of Docetaxel can be increased when combined with Fosphenytoin.Approved
FotemustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fotemustine.Experimental, Investigational
FulvestrantThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fulvestrant.Approved, Investigational
FumagillinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fumagillin.Experimental
Fusidic AcidThe serum concentration of Docetaxel can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Docetaxel.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gallium nitrate.Approved, Investigational
GarenoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gatifloxacin.Approved, Investigational
GefitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Geldanamycin.Experimental, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemcitabine.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemtuzumab ozogamicin.Approved
GenisteinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Docetaxel.Investigational
Ginsenoside CThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ginsenoside C.Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Docetaxel.Experimental
GlyphosateThe metabolism of Docetaxel can be decreased when combined with Glyphosate.Experimental
GoserelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Goserelin.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Grepafloxacin.Investigational, Withdrawn
GriseofulvinThe metabolism of Docetaxel can be decreased when combined with Griseofulvin.Approved, Vet Approved
GS 0573The risk or severity of adverse effects can be increased when Docetaxel is combined with GS 0573.Investigational
GusperimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gusperimus.Investigational
HachimycinThe metabolism of Docetaxel can be decreased when combined with Hachimycin.Experimental
HadacidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hadacidin.Experimental
HalofuginoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Halofuginone.Investigational, Vet Approved
HaloproginThe metabolism of Docetaxel can be decreased when combined with Haloprogin.Approved, Withdrawn
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Docetaxel.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Docetaxel.Approved, Withdrawn
HexestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hexestrol.Withdrawn
HexetidineThe metabolism of Docetaxel can be decreased when combined with Hexetidine.Approved, Investigational
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyprogesterone caproate.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hypericin.Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ibrutinib.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Docetaxel can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ifosfamide.Approved
ImatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imatinib.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imiquimod.Approved, Investigational
IndinavirThe metabolism of Docetaxel can be decreased when combined with Indinavir.Approved
IndirubinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Indirubin.Investigational
Indole-3-carbinolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Indole-3-carbinol.Investigational
InfigratinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Infigratinib.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Docetaxel.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Docetaxel.Investigational
IniparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Iniparib.Experimental, Investigational
Interferon Alfa-2b, RecombinantThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon Alfa-2b, Recombinant.Approved
Interferon beta-1aThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1a.Approved, Investigational
IobenguaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Iobenguane.Approved, Investigational
IpilimumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ipilimumab.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.Approved, Investigational
IrofulvenThe risk or severity of adverse effects can be increased when Docetaxel is combined with Irofulven.Investigational
IrsogladineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Irsogladine.Investigational
IsavuconazoniumThe metabolism of Docetaxel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe metabolism of Docetaxel can be decreased when combined with Isoconazole.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Isosorbide.Approved, Investigational
IsradipineThe metabolism of Docetaxel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Docetaxel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Docetaxel can be increased when it is combined with Ivacaftor.Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixabepilone.Approved, Investigational
IxazomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixazomib.Approved
KetoconazoleThe metabolism of Docetaxel can be decreased when combined with Ketoconazole.Approved, Investigational
KOS-1584The risk or severity of adverse effects can be increased when Docetaxel is combined with KOS-1584.Investigational
KRN-7000The risk or severity of adverse effects can be increased when Docetaxel is combined with KRN-7000.Investigational
L-alanosineThe risk or severity of adverse effects can be increased when Docetaxel is combined with L-alanosine.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Docetaxel.Experimental
LanreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lanreotide.Approved
LapatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lapatinib.Approved, Investigational
LCL-161The risk or severity of adverse effects can be increased when Docetaxel is combined with LCL-161.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.Approved
LentinanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lentinan.Experimental, Investigational
LenvatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.Approved
LetrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Letrozole.Approved, Investigational
LeuprolideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin.Approved, Investigational
LiarozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Liarozole.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Docetaxel.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomefloxacin.Approved, Investigational
LometrexolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lometrexol.Investigational
LomustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomustine.Approved
LonidamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lonidamine.Approved, Investigational
LopinavirThe metabolism of Docetaxel can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Docetaxel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Docetaxel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Docetaxel can be decreased when it is combined with Lumacaftor.Approved
LurtotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lurtotecan.Investigational
LycopeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lycopene.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Docetaxel.Illicit, Investigational, Withdrawn
MafosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mafosfamide.Investigational
MannosulfanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mannosulfan.Experimental
MasitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masitinib.Investigational, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masoprocol.Approved, Investigational
MaxacalcitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Maxacalcitol.Approved, Investigational
MebendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mebendazole.Approved, Vet Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mechlorethamine.Approved
MedrogestoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Megestrol acetate.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.Approved
MepartricinThe metabolism of Docetaxel can be decreased when combined with Mepartricin.Experimental
MequinolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mequinol.Approved
MercaptopurineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mercaptopurine.Approved
MerestinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Merestinib.Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Docetaxel.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Docetaxel.Experimental
MethotrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.Approved
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyl aminolevulinate.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Docetaxel.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone.Approved, Vet Approved
MethylselenocysteineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methylselenocysteine.Investigational
MethyltestosteroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Docetaxel.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Docetaxel.Experimental
MetoprineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Metoprine.Experimental
MevastatinThe metabolism of Docetaxel can be decreased when combined with Mevastatin.Experimental
MicafunginThe metabolism of Docetaxel can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Docetaxel can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidostaurinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Docetaxel can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Docetaxel can be decreased when combined with Miltefosine.Approved
MisonidazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Misonidazole.Investigational
MitobronitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitobronitol.Experimental
MitoguazoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoguazone.Investigational
MitolactolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitolactol.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.Approved
MitotaneThe serum concentration of Docetaxel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mizoribine.Investigational
MLN576The risk or severity of adverse effects can be increased when Docetaxel is combined with MLN576.Investigational
MolgramostimThe risk or severity of adverse effects can be increased when Docetaxel is combined with Molgramostim.Investigational
MonensinThe metabolism of Docetaxel can be decreased when combined with Monensin.Vet Approved
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Docetaxel is combined with motexafin gadolinium.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.Approved
MyxothiazolThe metabolism of Docetaxel can be decreased when combined with Myxothiazol.Experimental
NadifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nadifloxacin.Investigational
NaftifineThe metabolism of Docetaxel can be decreased when combined with Naftifine.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nalidixic Acid.Approved, Investigational
NamitecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Namitecan.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.Approved, Investigational
NatamycinThe metabolism of Docetaxel can be decreased when combined with Natamycin.Approved
NavitoclaxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Navitoclax.Investigational
NebularineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nebularine.Experimental
NecitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Necitumumab.Approved
NedaplatinNedaplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
NefazodoneThe metabolism of Docetaxel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Docetaxel can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Docetaxel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Docetaxel can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Docetaxel.Approved, Investigational
NifuratelThe metabolism of Docetaxel can be decreased when combined with Nifuratel.Experimental
NiguldipineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.Experimental
Nikkomycin ZThe metabolism of Docetaxel can be decreased when combined with Nikkomycin Z.Investigational
NilotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilotinib.Approved, Investigational
NilutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilutamide.Approved
NimustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nimustine.Investigational
NintedanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nintedanib.Approved
NiraparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Niraparib.Approved, Investigational
NitroxolineThe metabolism of Docetaxel can be decreased when combined with Nitroxoline.Approved
NivolumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nivolumab.Approved
nocodazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with nocodazole.Experimental
NolatrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nolatrexed.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Norfloxacin.Approved
NOV-002NOV-002 may increase the myelosuppressive activities of Docetaxel.Investigational
NystatinThe metabolism of Docetaxel can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.Approved
OblimersenThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oblimersen.Experimental, Investigational
OBP-801The risk or severity of adverse effects can be increased when Docetaxel is combined with OBP-801.Investigational
OctreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Octreotide.Approved, Investigational
OfatumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofatumumab.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofloxacin.Approved
OglufanideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oglufanide.Investigational
OlaparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Docetaxel.Experimental, Investigational
OltiprazThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oltipraz.Investigational
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Omacetaxine mepesuccinate.Approved
OmoconazoleThe metabolism of Docetaxel can be decreased when combined with Omoconazole.Experimental
OnapristoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Onapristone.Investigational
OprelvekinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Docetaxel can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Docetaxel.Approved
OxaliplatinOxaliplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
OxiconazoleThe metabolism of Docetaxel can be decreased when combined with Oxiconazole.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oxolinic acid.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Docetaxel.Approved, Vet Approved
Paclitaxel poliglumexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Paclitaxel poliglumex.Experimental, Investigational
pafuramidineThe metabolism of Docetaxel can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Docetaxel can be increased when it is combined with Palbociclib.Approved
PalifosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Palifosfamide.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pamidronate.Approved
PanitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panobinostat.Approved, Investigational
PatupiloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Patupilone.Experimental, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pegaspargase.Approved, Investigational
PembrolizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.Approved, Investigational
PenclomedineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Penclomedine.Investigational
PentamidineThe metabolism of Docetaxel can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Docetaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pentostatin.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Docetaxel.Approved, Investigational, Vet Approved, Withdrawn
PertuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pertuzumab.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Docetaxel.Experimental
Phenethyl IsothiocyanateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Phenethyl Isothiocyanate.Investigational
PhenobarbitalThe metabolism of Docetaxel can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Phenylacetic acid.Approved
Phenylbutyric acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe metabolism of Docetaxel can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Docetaxel.Approved, Investigational
PinometostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pinometostat.Investigational
PipobromanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pipobroman.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirfenidone.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Docetaxel.Approved
PixantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pixantrone.Approved, Investigational
PlevitrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Plevitrexed.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Plicamycin.Approved, Investigational, Withdrawn
PodofiloxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podofilox.Approved
PodophyllinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podophyllin.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ponatinib.Approved
Porfimer sodiumThe risk or severity of adverse effects can be increased when Docetaxel is combined with Porfimer sodium.Approved, Investigational
porfiromycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with porfiromycin.Investigational
PosaconazoleThe metabolism of Docetaxel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Docetaxel.Approved
PrednimustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednimustine.Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Docetaxel can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Procarbazine.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Docetaxel.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prulifloxacin.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Puromycin.Experimental
PyrazoloacridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pyrazoloacridine.Investigational
PyrrolnitrinThe metabolism of Docetaxel can be decreased when combined with Pyrrolnitrin.Experimental
QuinacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Quinacrine.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Docetaxel.Approved
RabusertibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rabusertib.Investigational
RadicicolThe metabolism of Docetaxel can be decreased when combined with Radicicol.Experimental
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Raltitrexed.Approved, Investigational
RamucirumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ramucirumab.Approved, Investigational
RanibizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranibizumab.Approved
RanimustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranimustine.Experimental
RanolazineThe serum concentration of Docetaxel can be increased when it is combined with Ranolazine.Approved, Investigational
RanpirnaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranpirnase.Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Regorafenib.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rhodamine 6G.Experimental
RidaforolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ridaforolimus.Investigational
RifabutinThe metabolism of Docetaxel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Docetaxel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Docetaxel can be increased when combined with Rifapentine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Docetaxel.Investigational
RituximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Docetaxel.Approved
RolapitantThe serum concentration of Docetaxel can be increased when it is combined with Rolapitant.Approved
RomidepsinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romidepsin.Approved, Investigational
RoquinimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Roquinimex.Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Docetaxel.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Docetaxel.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Docetaxel.Approved
RubitecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rubitecan.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rucaparib.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib.Approved
Salicylhydroxamic AcidThe metabolism of Docetaxel can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Docetaxel can be decreased when combined with Salicylic acid.Approved, Vet Approved
SalirasibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Salirasib.Investigational
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Docetaxel.Approved
SaquinavirThe metabolism of Docetaxel can be decreased when combined with Saquinavir.Approved, Investigational
SaracatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Saracatinib.Investigational
SatraplatinSatraplatin may increase the myelosuppressive activities of Docetaxel.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seliciclib.Investigational
SemaxanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Semaxanib.Investigational
SemustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Semustine.Experimental, Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seocalcitol.Experimental, Investigational
SertaconazoleThe metabolism of Docetaxel can be decreased when combined with Sertaconazole.Approved
SildenafilThe metabolism of Docetaxel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Docetaxel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Docetaxel can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Docetaxel.Approved
SinefunginThe metabolism of Docetaxel can be decreased when combined with Sinefungin.Experimental
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Docetaxel.Approved
SirolimusThe metabolism of Docetaxel can be decreased when combined with Sirolimus.Approved, Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sitafloxacin.Experimental, Investigational
SizofiranThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sizofiran.Investigational
SoblidotinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Soblidotin.Investigational
SonidegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sonidegib.Approved, Investigational
SorafenibThe serum concentration of Docetaxel can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfloxacin.Approved, Investigational
Sparfosic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfosic acid.Experimental
SparsomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparsomycin.Experimental
squalamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with squalamine.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Docetaxel.Investigational
SRT501The risk or severity of adverse effects can be increased when Docetaxel is combined with SRT501.Investigational
St. John's WortThe serum concentration of Docetaxel can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Docetaxel can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Streptozocin.Approved
SulconazoleThe metabolism of Docetaxel can be decreased when combined with Sulconazole.Approved
SulfisoxazoleThe metabolism of Docetaxel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulforaphane.Investigational
SulindacThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulindac.Approved
SunitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sunitinib.Approved, Investigational
SuraminThe risk or severity of adverse effects can be increased when Docetaxel is combined with Suramin.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Docetaxel.Approved, Investigational
TalaporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Talaporfin.Investigational
TalazoparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Talazoparib.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tamoxifen.Approved
TaselisibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Taselisib.Investigational
TaurolidineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Taurolidine.Investigational
TavaboroleThe metabolism of Docetaxel can be decreased when combined with Tavaborole.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Docetaxel.Investigational
TegafurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tegafur.Approved
TelaprevirThe metabolism of Docetaxel can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Docetaxel can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temafloxacin.Withdrawn
TemoporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temoporfin.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Teniposide.Approved
TerbinafineThe metabolism of Docetaxel can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Docetaxel can be decreased when combined with Terconazole.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Docetaxel.Experimental
TeriflunomideThe serum concentration of Docetaxel can be increased when it is combined with Teriflunomide.Approved
TestolactoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Testolactone.Approved, Investigational
TezacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tezacitabine.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Docetaxel.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thiotepa.Approved
ThymalfasinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thymalfasin.Approved, Investigational
ThymolThe metabolism of Docetaxel can be decreased when combined with Thymol.Approved
TiazofurineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tiazofurine.Experimental
TiboloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Docetaxel can be decreased when combined with Ticlopidine.Approved
TioconazoleThe metabolism of Docetaxel can be decreased when combined with Tioconazole.Approved
TioguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tioguanine.Approved
Tiomolibdate ionThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tiomolibdate ion.Investigational
TipifarnibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tipifarnib.Investigational
TirapazamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tirapazamine.Investigational
TivozanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tivozanib.Investigational
TocilizumabThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDocetaxel may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolciclateThe metabolism of Docetaxel can be decreased when combined with Tolciclate.Experimental
TolnaftateThe metabolism of Docetaxel can be decreased when combined with Tolnaftate.Approved, Vet Approved
TopotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Topotecan.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.Approved, Investigational
ToyocamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Toyocamycin.Experimental
TrabectedinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trabectedin.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trametinib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trastuzumab emtansine.Approved
TrebananibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trebananib.Investigational
TremelimumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tremelimumab.Investigational
TreosulfanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Treosulfan.Investigational
TretazicarThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tretazicar.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriaziquoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triaziquone.Experimental
TrifluridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trifluridine.Approved
TrilostaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateThe metabolism of Docetaxel can be decreased when combined with Trimetrexate.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptolide.Investigational
TriptorelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptorelin.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trofosfamide.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Troxacitabine.Investigational
TubercidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tubercidin.Experimental
UbenimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Docetaxel.Approved, Experimental
Uracil mustardThe risk or severity of adverse effects can be increased when Docetaxel is combined with Uracil mustard.Approved
VadimezanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vadimezan.Investigational
ValrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Valrubicin.Approved
VandetanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vandetanib.Approved
VapreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vapreotide.Approved, Investigational
VeliparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Veliparib.Investigational
VemurafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vemurafenib.Approved
VenetoclaxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Venetoclax.Approved
VenlafaxineThe metabolism of Docetaxel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Docetaxel can be decreased when combined with Verapamil.Approved
VerteporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Verteporfin.Approved, Investigational
VesnarinoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vesnarinone.Investigational
VinblastineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vindesine.Approved, Investigational
VinflunineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinflunine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.Approved, Investigational
VintafolideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vintafolide.Investigational
VismodegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vismodegib.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Docetaxel can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat.Approved, Investigational
VorozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vorozole.Experimental
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Docetaxel.Approved
ZiprasidoneThe metabolism of Docetaxel can be decreased when combined with Ziprasidone.Approved
ZorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Zorubicin.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Docetaxel.Approved
Zuretinol acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Zuretinol acetate.Investigational
Food Interactions
Not Available

References

Synthesis Reference

Nicholas J. Sisti, Charles S. Swindell, "Method for docetaxel synthesis." U.S. Patent US5688977, issued September, 1991.

US5688977
General References
Not Available
External Links
Human Metabolome Database
HMDB15378
KEGG Drug
D02165
KEGG Compound
C11231
PubChem Compound
148124
PubChem Substance
46506766
ChemSpider
130581
BindingDB
36351
ChEBI
4672
ChEMBL
CHEMBL92
Therapeutic Targets Database
DAP000590
PharmGKB
PA449383
HET
TXL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Docetaxel
ATC Codes
L01CD02 — Docetaxel
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1ia0 / 1tub
FDA label
Download (140 KB)
MSDS
Download (100 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentCancer, Breast1
0CompletedTreatmentHead and Neck Carcinoma1
0RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingOtherProstate Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Prostate1
1Active Not RecruitingTreatmentAdvanced Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced1
1Active Not RecruitingTreatmentAdvanced Solid Tumors1
1Active Not RecruitingTreatmentCancer, Breast / Colon Neoplasms / Lung Cancers / Malignant Neoplasm of Colon / Melanoma / Neoplasms, Breast / Renal Cancers1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1Active Not RecruitingTreatmentNeoplasms, Breast1
1Active Not RecruitingTreatmentNeoplasms / Solid Cancers1
1Active Not RecruitingTreatmentProstate Cancer2
1Active Not RecruitingTreatmentTumors, Solid1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedNot AvailableMalignant Neoplasm of Stomach1
1CompletedTreatmentAdenocarcinoma of the Prostate / Advanced Solid Tumors1
1CompletedTreatmentAdvanced Neoplastic Disease1
1CompletedTreatmentAdvanced Non-Hematologic Malignancies1
1CompletedTreatmentAdvanced Solid Tumors5
1CompletedTreatmentAdvanced Solid Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Cancer, Ovarian / Carcinoma of Unknown Primary / Esophageal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Melanoma (Skin) / Prostate Cancer / Sarcomas1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Cancer, Ovarian / Lung Cancers / Prostate Cancer / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBreast Cancer, Non-small Lung Cancer1
1CompletedTreatmentBrenner Tumor / Fallopian Tube Cancer / Ovarian Carcinosarcoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Primary Peritoneal Cavity Cancer / Stage II Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentCancer of Parotid / Head and Neck Carcinoma / Malignant Neoplasm of Thyroid / Melanoma / Parotid Gland Cancer / Stage IV Head and Neck Cancer / Thyroid neoplasms malignant1
1CompletedTreatmentCancer, Advanced3
1CompletedTreatmentCancer, Breast6
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Esophageal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Stomach / Prostate Cancer1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Head and Neck Carcinoma / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Malignant Neoplasm of Pancreas / Non-Small Cell Lung / Tumors, Solid1
1CompletedTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Prostate Cancer1
1CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentCancer, Breast / Neutropenias1
1CompletedTreatmentCancer, Neoplasms, Tumors1
1CompletedTreatmentCancer, Ovarian1
1CompletedTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Peritoneal Cavity Cancer / Sarcomas / Vaginal Cancers / Vulvar Cancers1
1CompletedTreatmentCancer, Ovarian / Endometrial Cancers / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancers6
1CompletedTreatmentCancers / Carcinoma NOS1
1CompletedTreatmentCancers / Neoplasms / Tumors1
1CompletedTreatmentCancers / Prophylaxis of acute chemotherapy induced nausea and vomiting1
1CompletedTreatmentEsophageal Cancers2
1CompletedTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
1CompletedTreatmentHER-2 Gene Amplification1
1CompletedTreatmentHNSCC1
1CompletedTreatmentHead & Neck Cancer1
1CompletedTreatmentHead and Neck Carcinoma3
1CompletedTreatmentLocally Advanced, Metastatic Solid Tumors1
1CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1CompletedTreatmentLung Cancers1
1CompletedTreatmentMalignant Diseases1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMalignant Neoplasm of Stomach1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentMetastatic Cancers1
1CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
1CompletedTreatmentMetastatic Melanoma1
1CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentNeoplasms7
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms, Breast1
1CompletedTreatmentNeoplasms, Esophageal1
1CompletedTreatmentNeoplasms, Head and Neck1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentOvarian Carcinoma1
1CompletedTreatmentProstate Cancer10
1CompletedTreatmentProstatic Neoplasms2
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentRecurrent Prostate Cancer / Stage IV Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentResistant Solid Malignancies1
1CompletedTreatmentSarcomas1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentSolid Tumor Cancers2
1CompletedTreatmentSolid Tumor Malignancies1
1CompletedTreatmentSquamous Cell Carcinoma of Esophagus1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid6
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific17
1Not Yet RecruitingOtherNeoplasms, Advanced Solid1
1Not Yet RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Estrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Metastatic Malignant Solid Neoplasm / Progesterone Receptor Negative / PTEN gene mutation / Triple-Negative Breast Carcinoma / Unresectable Solid Neoplasm1
1Not Yet RecruitingTreatmentImpaired Renal Function1
1RecruitingBasic ScienceNeoplasms1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingOtherAdvanced Solid Tumors, Neoplasms, Advanced Solid1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Head and Neck Squamous Cell Carcinoma (HNSCC) / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1RecruitingTreatmentFumarate Hydratase (FH)-Deficient Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma / Renal Cell Adenocarcinoma / Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) / Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors / Triple-Negative Breast Cancer (TNBC) / Tumors Harboring Amplifications in the cMyc Gene / Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations / Tumors, Solid1
1RecruitingTreatmentHER2 Positive Breast Cancers / Her2-negative Metastatic Breast Cancer / HER2-positive Metastatic Breast Cancer / Locally Advanced or Early Breast Cancer1
1RecruitingTreatmentHead and Neck Carcinoma2
1RecruitingTreatmentHead and Neck Carcinoma / Salivary Gland Tumors1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
1RecruitingTreatmentInflammatory carcinoma of the breast1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentLung Cancers1
1RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Prostatic Neoplasms1
1RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
1RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
1RecruitingTreatmentMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Bladder Carcinoma / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage III Bladder Urothelial Carcinoma / Stage III Urethral Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Urethral Cancer / Urethral Urothelial Carcinoma1
1RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentProstate Cancer1
1RecruitingTreatmentProstatic Neoplasms1
1RecruitingTreatmentRecurrent Non-small Cell Lung Cancer1
1RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
1RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1SuspendedTreatmentCancers1
1TerminatedNot AvailableNon-hematologic Malignancies / Pharmacokinetics of ASP98531
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
1TerminatedTreatmentAdvanced Malignancies, Non-small Cell Lung Cancer1
1TerminatedTreatmentAdvanced Solid Tumors1
1TerminatedTreatmentBladder Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-small Cell Lung, Prostate, Bladder/Urothelial Cancers / Prostate Cancer / Transitional Cell Carcinoma1
1TerminatedTreatmentBreast Cancer Metastatic1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentCancer, Breast / Carcinoma, Colorectal / Lung Cancers / Prostate Cancer / Soft Tissue Sarcoma (STS)1
1TerminatedTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Malignant Neoplasm of Stomach / Prostate Cancer / Pulmonary Cancer1
1TerminatedTreatmentCervical Cancers1
1TerminatedTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Colon Cancer / Recurrent Non-small Cell Lung Cancer / Recurrent Rectal Cancer / Recurrent Small Cell Lung Cancer / Stage IV Colon Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Rectal Cancer1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1TerminatedTreatmentLung Cancers2
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNeoplasms, Advanced or Metastatic1
1TerminatedTreatmentOncology, Medical1
1TerminatedTreatmentProstate Cancer / Prostate Cancer Metastatic Disease / Urologic Neoplasms1
1TerminatedTreatmentTumors1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentCancer, Advanced1
1Unknown StatusTreatmentProstate Cancer2
1Unknown StatusTreatmentTumors, Solid1
1WithdrawnTreatmentCancer, Breast1
1WithdrawnTreatmentCancer, Breast / Head and Neck Carcinoma / Lung Cancers / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentCancer, Ovarian / Ovarian Carcinoma / Recurrent Ovarian Cancer / Recurrent Ovarian Carcinoma1
1WithdrawnTreatmentChemotherapeutic Agent Toxicity / Lung Cancers1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1WithdrawnTreatmentProstatic Neoplasms1
1WithdrawnTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
1WithdrawnTreatmentTumors, Solid1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2Active Not RecruitingTreatmentCancer, Advanced / Cancer, Breast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2Active Not RecruitingTreatmentEsophageal Cancers1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2Active Not RecruitingTreatmentProstate Cancer2
1, 2Active Not RecruitingTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentAdult Solid Neoplasm / Inflammatory Breast Carcinoma / Male Breast Carcinoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
1, 2CompletedTreatmentAdvanced Squamous Cell Carcinoma / Squamous Cell Carcinoma of Head and Neck / SSCHN1
1, 2CompletedTreatmentBladder Cancers / Cancer, Breast / Cancer, Ovarian / Colorectal Cancers / Esophageal Cancers / Head and Neck Carcinoma / Lung Cancers / Prostate Cancer / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentBone Metastases / Castration-Resistant Prostate Cancer (CRPC)1
1, 2CompletedTreatmentCancer of Head and Neck / Head and Neck Carcinoma / Head Cancer / Neck Cancer / Neoplasms, Neck1
1, 2CompletedTreatmentCancer of the Breast1
1, 2CompletedTreatmentCancer, Breast6
1, 2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2CompletedTreatmentCancers1
1, 2CompletedTreatmentCarcinoma of Head and/or Neck / Squamous Cell Carcinoma (SCC)1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentEsophageal Cancers3
1, 2CompletedTreatmentEsophagus Cancer1
1, 2CompletedTreatmentFallopian Tube Cancer / Malignant Tumor of Peritoneum / Recurrent Ovarian Epithelial Cancer1
1, 2CompletedTreatmentGastrointestinal Diseases1
1, 2CompletedTreatmentHead and Neck Carcinoma1
1, 2CompletedTreatmentLocally Advanced Sarcoma / Metastatic Sarcoma / Sarcomas / Soft Tissue Sarcoma (STS) / Unresectable Sarcoma1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2CompletedTreatmentLung Cancers4
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentMalignant Neoplasm of Stomach2
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)2
1, 2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
1, 2CompletedTreatmentMetastatic, Androgen Independent Prostate Cancer / Prostate Cancer1
1, 2CompletedTreatmentNeoplasms, Breast1
1, 2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
1, 2CompletedTreatmentNeoplasms, Head and Neck1
1, 2CompletedTreatmentOperable Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentOropharynx Cancers / Squamous Cell Carcinoma of the Oral Cavity1
1, 2CompletedTreatmentProstate Cancer6
1, 2CompletedTreatmentProstate Cancer / Tumors1
1, 2CompletedTreatmentProstatic Neoplasms2
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung1
1, 2CompletedTreatmentRecurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Salivary Gland Squamous Cell Carcinoma / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity1
1, 2CompletedTreatmentStomach Neoplasms1
1, 2CompletedTreatmentTumors, Solid1
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
1, 2RecruitingTreatmentAdvanced Solid Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentCancer, Breast / Cholangiocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Solid Tumours / MPN / Multiple Myeloma (MM) / Neoplasms, Endometrial / Stomach Neoplasms / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentCastration Levels of Testosterone / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentColorectal Adenocarcinoma (CRC) / Gastric Adenocarcinoma / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentColorectal Cancers1
1, 2RecruitingTreatmentHead and Neck Carcinoma1
1, 2RecruitingTreatmentLocally Advanced or Metastatic Urothelial Cell Carcinoma / Urinary Bladder Diseases / Urological Diseases1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Colorectal / Neoplasms, Gastrointestinal / Neoplasms, Pancreatic1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Cancer Recurrent / Progression of Non-small Cell Lung Cancer1
1, 2RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
1, 2RecruitingTreatmentProstate Cancer1
1, 2RecruitingTreatmentSarcomas1
1, 2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1, 2SuspendedTreatmentMalignant Neoplasm of Stomach1
1, 2TerminatedTreatmentAdenocarcinoma of the Prostate / Prostate Cancer / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
1, 2TerminatedTreatmentAny Cancer / Cancer, Breast1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentExtensive Stage Unresectable / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2TerminatedTreatmentLung Cancers1
1, 2TerminatedTreatmentMale Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentPain / Prostate Cancer1
1, 2TerminatedTreatmentProstate Cancer2
1, 2TerminatedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2TerminatedTreatmentSquamous Non-Small Cell Lung Cancer1
1, 2Unknown StatusTreatmentAdvanced Gastric Cancer1
1, 2Unknown StatusTreatmentCancer of the Esophagus / Gastric Cardia Carcinoma1
1, 2Unknown StatusTreatmentCancer, Ovarian1
1, 2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2Unknown StatusTreatmentCastrate-resistant Prostate Cancer (CRPC)1
1, 2Unknown StatusTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers1
1, 2Unknown StatusTreatmentEsophageal Cancers1
1, 2Unknown StatusTreatmentHormone Refractory Prostate Cancer1
1, 2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2Unknown StatusTreatmentNeoplasms, Head and Neck1
1, 2Unknown StatusTreatmentProstate Cancer1
1, 2WithdrawnTreatmentCervical Cancers1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2Active Not RecruitingNot AvailableAdenocarcinoma of the Gastro-oesophageal Junction / Metastatic Gastric Cancers1
2Active Not RecruitingBasic ScienceStage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Prostatic Adenocarcinoma / Recurrent Prostate Carcinoma1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Malignant Neoplasm of Stomach2
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentAdvanced Gastric Cancer1
2Active Not RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentAnal Canal Carcinoma1
2Active Not RecruitingTreatmentCancer, Breast12
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Active Not RecruitingTreatmentChemoradiation / Neoplasms, Esophageal1
2Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentGastric Adenocarcinoma With Peritoneal Carcinomatosis / Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis / Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis1
2Active Not RecruitingTreatmentHead and Neck Carcinoma4
2Active Not RecruitingTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentHuman Papillomavirus Infections / Stage I Oropharyngeal Squamous Cell Carcinoma / Stage II Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
2Active Not RecruitingTreatmentHypopharyngeal Cancer1
2Active Not RecruitingTreatmentLeiomyosarcomas1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentMalignant Neoplasm of Female Breast1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach2
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Unresectable1
2Active Not RecruitingTreatmentMalignant Tumor of the Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentNeoplasms1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentProstate Cancer3
2Active Not RecruitingTreatmentProstate Cancer Metastatic Castration Resistant1
2Active Not RecruitingTreatmentProstatic Neoplasms3
2Active Not RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Hypopharynx Stage III / Squamous Cell Carcinoma of the Hypopharynx Stage IV / Squamous Cell Carcinoma of the Larynx Stage III / Squamous Cell Carcinoma of the Larynx Stage IV / Squamous Cell Carcinoma of the Oral Cavity Stage III / Squamous Cell Carcinoma of the Oral Cavity Stage IV / Squamous Cell Carcinoma of the Oropharynx Stage III / Squamous Cell Carcinoma of the Oropharynx Stage IV1
2CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedNot AvailableMetastatic Hormone Refractory Prostate Cancer1
2CompletedPreventionGrade 3/4 Neutropenia / Neutropenia, Febrile1
2CompletedPreventionProstate Cancer1
2CompletedPreventionUnresectable Locally Advanced NSCLC1
2CompletedTreatmentAbdominal wall neoplasm / Ovarian Carcinoma1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Gastric Adenocarcinoma1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Recurrent Esophageal Cancer / Squamous Cell Carcinoma of the Esophagus / Stage IV Esophageal Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Malignant Pleural Effusions / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Prostate Cancer2
2CompletedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentAdenocarcinoma, Prostate1
2CompletedTreatmentAdenocarcinomas of the Esophagogastric Junction / Malignant Neoplasm of Stomach2
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2CompletedTreatmentAdrenocortical Carcinoma1
2CompletedTreatmentAdvanced Breast Cancer1
2CompletedTreatmentAdvanced Endometrial Adenocarcinoma, Stage III A, B, C1
2CompletedTreatmentAdvanced Gastric Cancer1
2CompletedTreatmentAdvanced Gastric Cancer / Gastro-esophageal Junction Cancer1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentAmpullary Cancer / Cholangiocarcinoma Cancer / Gallbladder Cancer / Malignant Neoplasm of Pancreas1
2CompletedTreatmentAnemias / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Neutropenias1
2CompletedTreatmentBiliary Tract Neoplasms / Neoplasms, Pancreatic1
2CompletedTreatmentBladder Cancers3
2CompletedTreatmentBladder Cancers / Cancer, Breast / Head and Neck Carcinoma / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBladder Cancers / Transitional Cell Carcinoma2
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Sarcomas1
2CompletedTreatmentCancer of Esophagus / Cancer of the Esophagus / Esophageal Cancers / Esophagus Cancer / Neoplasms, Esophageal1
2CompletedTreatmentCancer, Breast72
2CompletedTreatmentCancer, Breast / Fevers / Neutropenias1
2CompletedTreatmentBrca1 Mutation Carrier / Brca2 Mutation Carrier / Cancer, Breast / Hereditary Breast/Ovarian Cancer (brca1, brca2)1
2CompletedTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentCancer, Breast / Lung Cancers / Prostate Cancer1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Tumors, Solid1
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis2
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian4
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Tumor of Peritoneum1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer3
2CompletedTreatmentCancer, Ovarian / Peritoneal Cavity Cancer3
2CompletedTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentCancers1
2CompletedTreatmentCarcinoma NOS / Nasopharyngeal Neoplasms1
2CompletedTreatmentCarcinoma of Head/Neck / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoma of Larynx / Squamous Cell Carcinoma of the Hypopharynx1
2CompletedTreatmentCarcinoma of Renal Pelvis / Carcinoma of Ureter / Carcinoma of Urinary Tract / Urethral Carcinoma1
2CompletedTreatmentCervical Cancers2
2CompletedTreatmentCervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Recurrent Cervical Carcinoma1
2CompletedTreatmentCervix Neoplasms1
2CompletedTreatmentCervix Neoplasms / Neoplasms, Lung / Neoplasms, Ovarian / Renal Neoplasms1
2CompletedTreatmentERBB2 Gene Amplification / Neoplasms Metastasis / Stomach Neoplasms1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEsophageal Cancers4
2CompletedTreatmentEsophageal Cancers / GE Junction Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach6
2CompletedTreatmentFemale Breast Cancer1
2CompletedTreatmentGastric Adenocarcinoma1
2CompletedTreatmentGastric Cancer Adenocarcinoma Metastatic1
2CompletedTreatmentGastro Oesophageal Cancer1
2CompletedTreatmentHER-2 Positive Metastatic Breast Cancer1
2CompletedTreatmentHER2 Negative Breast Cancer1
2CompletedTreatmentHead and Neck Carcinoma16
2CompletedTreatmentHead and Neck Carcinoma / Squamous Cell Cancer1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2CompletedTreatmentHead and Neck / Head and Neck Carcinoma / Recurrent Disease / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentHemangiosarcoma / Histiocytoma / Leiomyosarcomas / Malignant Fibrous / Sarcomas1
2CompletedTreatmentHormone Refractory Prostate Cancer1
2CompletedTreatmentHormone Refractory / Metastatic / Prostate Cancer1
2CompletedTreatmentHormone Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer1
2CompletedTreatmentHormone-Refractory Prostate Cancer2
2CompletedTreatmentIndividualized Chemotherapy1
2CompletedTreatmentLeiomyosarcomas / Uterine Neoplasms1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)45
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers2
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentLung Cancers30
2CompletedTreatmentMalignant Gastrointestinal Stromal Tumor / Sarcomas1
2CompletedTreatmentMalignant Neoplasm of Pancreas11
2CompletedTreatmentMalignant Neoplasm of Stomach8
2CompletedTreatmentMalignant Neoplasm of Stomach / Neoplasms, Esophageal1
2CompletedTreatmentMalignant Neoplasm of Stomach / Peritoneal Carcinomatosis1
2CompletedTreatmentMalignant Pleural Effusions / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentMalignant Solid Tumours1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMetastatic Breast Cancer (MBC)10
2CompletedTreatmentMetastatic Cancers / Prostate Cancer3
2CompletedTreatmentMetastatic Carcinoma / Recurrent Esophageal Squamous Cell Carcinoma1
2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer3
2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer / Prostate Cancer1
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentMetastatic Non-Small Cell Lung Cancer1
2CompletedTreatmentMetastatic Pancreatic Carcinoma1
2CompletedTreatmentMetastatic Soft Tissue Sarcoma1
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Urothelial Tract1
2CompletedTreatmentMetastatic or Recurrent Squamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentNasopharyngeal Carcinoma2
2CompletedTreatmentNasopharyngeal Neoplasms2
2CompletedTreatmentNasopharyngeal Squamous Cell Carcinoma / Toxicity Due to Radiotherapy1
2CompletedTreatmentNeoplasms Metastasis / Stomach Neoplasms1
2CompletedTreatmentNeoplasms, Breast11
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms2
2CompletedTreatmentNeoplasms, Head and Neck4
2CompletedTreatmentNeoplasms, Lung4
2CompletedTreatmentNeoplasms, Ovarian2
2CompletedTreatmentNeoplasms, Ovarian / Uterine Neoplasms1
2CompletedTreatmentNon-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentOesophageal Carcinoma1
2CompletedTreatmentOvarian Carcinoma / Primary Peritoneal Carcinoma1
2CompletedTreatmentOvarian Clear Cell Cystadenocarcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2CompletedTreatmentOvarian Epithelial Cancer Recurrent1
2CompletedTreatmentPain / Prostate Cancer1
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPancreatic Cancer Stage IVA1
2CompletedTreatmentPathological Response Rate1
2CompletedTreatmentPrimary Breast Cancer1
2CompletedTreatmentProstate Cancer39
2CompletedTreatmentProstate Cancer / Thromboembolism1
2CompletedTreatmentProstatic Neoplasms7
2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer2
2CompletedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Carcinosarcoma1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Corpus Leiomyosarcoma1
2CompletedTreatmentResected Advanced Gastric Cancer1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentSquamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentStomach Neoplasms5
2CompletedTreatmentTherapy, Prostatic Neoplasms1
2CompletedTreatmentTumors, Solid1
2Not Yet RecruitingPreventionTransitional Cell Carcinoma1
2Not Yet RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
2Not Yet RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Not Yet RecruitingTreatmentCancer treatment / Castration-Resistant Prostate Cancer (CRPC) / Circulating Tumor Cells / Prostate Cancer1
2Not Yet RecruitingTreatmentLocally Advanced Breast Cancer (LABC)1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach2
2Not Yet RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
2Not Yet RecruitingTreatmentNeoplasm Neck1
2Not Yet RecruitingTreatmentProstate Cancer2
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentAdenocarcinoma of the Lung / Lung Cancers / Non-Squamous Non-Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentAdenocarcinoma, Prostate / Prostate Cancer1
2RecruitingTreatmentAdenocarcinomas / Carcinoma, Large Cell / Heregulin / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAdvanced Esophageal Squamous Carcinoma1
2RecruitingTreatmentAnterior Tongue Squamous Cell Carcinoma / Squamous Cell Carcinoma (SCC) / Tongue Neoplasms1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentBCT Rate / PCR Rate / Safety1
2RecruitingTreatmentBrenner Tumor / Malignant Ascites / Malignant Pleural Effusions / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Ovarian Germ Cell Tumor / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Ovarian Germ Cell Tumor / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Ovarian Germ Cell Tumor / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Primary Peritoneal Cavity Cancer1
2RecruitingTreatmentCancer, Breast8
2RecruitingTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Stomach / Prostate Cancer / Tumors, Solid1
2RecruitingTreatmentCancer, Breast / Neoplasms Metastasis1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
2RecruitingTreatmentDocetaxel, Oxaliplatin and Fluorouracil1
2RecruitingTreatmentEndometrial Cancers1
2RecruitingTreatmentGastric Adenocarcinoma1
2RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal-junction Adenocarcinoma1
2RecruitingTreatmentHER-2 Positive Breast Cancer1
2RecruitingTreatmentHead and Neck Carcinoma2
2RecruitingTreatmentHead and Neck Carcinoma / Larynx1
2RecruitingTreatmentHead and Neck Carcinoma / Recurrent1
2RecruitingTreatmentHead and Neck Carcinoma / Salivary Gland Tumors1
2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2RecruitingTreatmentHead-and-neck Cancer / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Stage IV Prostate Cancer1
2RecruitingTreatmentHypopharyngeal Cancer / Oropharyngeal Cancers1
2RecruitingTreatmentKRAS Gene Mutation / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
2RecruitingTreatmentLaryngeal Cancer1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)6
2RecruitingTreatmentMalignant Neoplasm of Stomach2
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentMetastatic Colorectal Adenocarcinoma1
2RecruitingTreatmentMetastatic Gastric Cancers1
2RecruitingTreatmentMetastatic Prostatic Adenocarcinoma1
2RecruitingTreatmentNasopharyngeal Carcinoma1
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeoplasms, Esophageal1
2RecruitingTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2RecruitingTreatmentNeoplasms, Lung1
2RecruitingTreatmentParanasal Sinus Neoplasms / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentProstate Cancer3
2RecruitingTreatmentProstate Cancer / Prostate Neoplasms / Prostatic Neoplasms1
2RecruitingTreatmentProstatic Neoplasms1
2RecruitingTreatmentRecurrent Head and Neck Cancer1
2RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2RecruitingTreatmentSarcoma, Osteogenic1
2RecruitingTreatmentSinonasal Tumors1
2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2RecruitingTreatmentSquamous Cell Carcinoma of Lung1
2RecruitingTreatmentStage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2RecruitingTreatmentTesticular Cancer1
2RecruitingTreatmentThyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2RecruitingTreatmentTriple Negative Breast Neoplasms1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentUnresectable Sinonasal Tumors1
2SuspendedTreatmentMetastatic Non-Small Cell Lung Cancer1
2SuspendedTreatmentProstate Cancer1
2TerminatedDiagnosticCancer, Breast1
2TerminatedDiagnosticHead and Neck Carcinoma1
2TerminatedPreventionProstate Cancer1
2TerminatedTreatmentAdenocarcinoma Of Esophagus / Adenocarcinomas of the Gastroesophageal Junction1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Stage IV Prostate Cancer1
2TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer2
2TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Stage IIIB or IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentBiliary Cancer2
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of Larynx1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2TerminatedTreatmentCancer, Breast14
2TerminatedTreatmentCancer, Ovarian3
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancers1
2TerminatedTreatmentCarcinoma of the Head and Neck1
2TerminatedTreatmentDuctal Carcinoma1
2TerminatedTreatmentEarly-Stage Breast Cancer1
2TerminatedTreatmentEsophageal Cancers2
2TerminatedTreatmentGastric Adenocarcinoma2
2TerminatedTreatmentHead and Neck Carcinoma2
2TerminatedTreatmentHead and Neck Carcinoma / Squamous Carcinoma1
2TerminatedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2TerminatedTreatmentHepatocellular,Carcinoma1
2TerminatedTreatmentHormone Refractory Prostate Cancer3
2TerminatedTreatmentHuman Papilloma Virus (HPV) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)16
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non Squamous Cell Lung Cancer1
2TerminatedTreatmentLung Cancers5
2TerminatedTreatmentMalignant Neoplasm of Pancreas2
2TerminatedTreatmentMalignant Neoplasm of Stomach3
2TerminatedTreatmentMediastinal Neoplasms1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)2
2TerminatedTreatmentMetastatic Hormone Refractory Prostate Cancer1
2TerminatedTreatmentNeoplasms, Breast2
2TerminatedTreatmentNeoplasms, Breast / Relapsed Breast Cancer1
2TerminatedTreatmentNeoplasms, Pancreatic1
2TerminatedTreatmentNeoplasms / Neoplasms, Head and Neck1
2TerminatedTreatmentOesophageal Carcinoma1
2TerminatedTreatmentOral Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentPenile Cancer1
2TerminatedTreatmentProstate Cancer12
2TerminatedTreatmentProstatic Neoplasms4
2TerminatedTreatmentRecurrent Bladder Cancer / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Unknown StatusBasic ScienceHormone Refractory Prostate Cancer1
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusSupportive CareSarcomas1
2Unknown StatusTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
2Unknown StatusTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Junction Adenocarcinoma1
2Unknown StatusTreatmentBiliary Tract Cancer1
2Unknown StatusTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2Unknown StatusTreatmentBreast Cancer Stage II / Breast Cancer Stage III1
2Unknown StatusTreatmentBreast Diseases / Cancer, Breast / Neoplasms / Neoplasms by Site1
2Unknown StatusTreatmentCancer, Breast11
2Unknown StatusTreatmentCancer, Ovarian / Endometrial Cancers / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2Unknown StatusTreatmentCarcinoma, Large Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Carcinoma1
2Unknown StatusTreatmentDrug Therapy / Genes, EGFR / Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC)1
2Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentHead and Neck Carcinoma2
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)12
2Unknown StatusTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentLung Cancers8
2Unknown StatusTreatmentMalignant Neoplasm of Nasopharynx1
2Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
2Unknown StatusTreatmentMalignant Neoplasm of Stomach4
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
2Unknown StatusTreatmentNasopharyngeal Carcinoma4
2Unknown StatusTreatmentNeoplasms, Breast1
2Unknown StatusTreatmentPain / Prostate Cancer1
2Unknown StatusTreatmentPancreas Neoplasms1
2Unknown StatusTreatmentProstate Cancer3
2Unknown StatusTreatmentProstatic Neoplasms1
2Unknown StatusTreatmentSarcomas1
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
2Unknown StatusTreatmentSquamous Cell Carcinoma of Lung1
2Unknown StatusTreatmentSquamous Cell Carcinoma of the Head / Squamous Cell Carcinoma of the Neck1
2Unknown StatusTreatmentStomach Neoplasms3
2WithdrawnDiagnosticStage IIIA Non-Small Cell Lung Cancer1
2WithdrawnTreatmentAdenocarcinoma of the Prostate / Prostate Cancer / Stage I Prostate Cancer / Stage II Prostate Cancer1
2WithdrawnTreatmentCancer, Breast6
2WithdrawnTreatmentCarcinoma of Unknown Primary1
2WithdrawnTreatmentHead and Neck Carcinoma1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2WithdrawnTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentNeoplasms, Breast2
2WithdrawnTreatmentProstate Cancer5
2WithdrawnTreatmentStage IV Non-Small Cell Lung Cancer1
2WithdrawnTreatmentTransitional Cell Carcinoma2
2WithdrawnTreatmentTumors, Solid1
2, 3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Cancer Recurrent / Progression of Non-small Cell Lung Cancer1
2, 3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2, 3Active Not RecruitingTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2, 3CompletedSupportive CareChemotherapy Induced Neutropenia1
2, 3CompletedTreatmentCisplatin Adverse Reaction / Upper GI Cancer1
2, 3CompletedTreatmentNeoplasm Recurrence, Local / Neoplasms Metastasis / Neoplasms, Head and Neck1
2, 3Not Yet RecruitingNot AvailableNasopharyngeal Carcinoma1
2, 3Not Yet RecruitingSupportive CareChemotherapy Induced Neutropenia1
2, 3Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2, 3Not Yet RecruitingTreatmentNon Small Cell Lung Cancer Stage IIIB / Non-Small Cell Carcinoma of Lung, TNM Stage 41
2, 3Not Yet RecruitingTreatmentStage III Breast Cancer1
2, 3RecruitingScreeningLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentCancer, Breast1
2, 3RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2, 3RecruitingTreatmentGastric Carcinoma1
2, 3RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2, 3RecruitingTreatmentProgression Free Survival1
2, 3RecruitingTreatmentProstate Cancer1
2, 3RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2, 3RecruitingTreatmentStage I Prostate Adenocarcinoma / Stage II Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma1
2, 3SuspendedTreatmentMetastatic Breast Cancer (MBC)1
2, 3TerminatedTreatmentActivating EGFR Mutation / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-squamous Non-small Cell Lung Cancer Stage II / Non-squamous Non-small Cell Lung Cancer Stage IIIA / Non-squamous Non-small Cell Lung Cancer Stage IIIB1
2, 3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer / Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB1
2, 3TerminatedTreatmentProstate Cancer1
2, 3Unknown StatusTreatmentLobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma1
2, 3Unknown StatusTreatmentLung Cancers1
2, 3Unknown StatusTreatmentPancreatic Cancer Stage II / Pancreatic Cancer Stage III1
2, 3Unknown StatusTreatmentProstate Cancer1
3Active Not RecruitingNot AvailableCancer, Breast1
3Active Not RecruitingOtherMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingPreventionLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentAdenocarcinoma, Mucinous / Carcinoma, Undifferentiated / Clear Cell Adenocarcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinofibroma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
3Active Not RecruitingTreatmentAnaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentBladder Cancers1
3Active Not RecruitingTreatmentCancer, Breast21
3Active Not RecruitingTreatmentCancer, Breast / Neoplasms, Breast2
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentEstrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Positive / Stage IB Breast Cancer / Stage IB Breast Cancer AJCC v7 / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer / Stage IIB Breast Cancer AJCC v6 and v7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v71
3Active Not RecruitingTreatmentHead and Neck Squamous Cell Cancer1
3Active Not RecruitingTreatmentHer2 Non-overexpressing / Primary Breast Cancer1
3Active Not RecruitingTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentMetastatic Castrate Resistant Prostate Cancer1
3Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentMetastatic Hormone-sensitive Prostate Cancer1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
3Active Not RecruitingTreatmentNeoplasms, Head and Neck1
3Active Not RecruitingTreatmentNon-Squamous Cell Non-small Cell Lung Cancer1
3Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer2
3Active Not RecruitingTreatmentProstate Cancer6
3Active Not RecruitingTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Major Salivary Gland Cancer AJCC v7 / Stage IV Major Salivary Gland Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Cancer AJCC v6 and v7 / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Cancer AJCC v6 and v7 / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Cancer AJCC v6 and v7 / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3Active Not RecruitingTreatmentSquamous Cell Non-small Cell Lung Cancer1
3Active Not RecruitingTreatmentStage I Uterine Sarcoma / Stage I Uterine Sarcoma AJCC v7 / Uterine Corpus Leiomyosarcoma1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v71
3Active Not RecruitingTreatmentTransitional Cell Carcinoma1
3Active Not RecruitingTreatmentUrothelial Cancer1
3CompletedNot AvailableEsophageal Cancers1
3CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedPreventionCancers1
3CompletedPreventionNon Small Cell Lung Carcinoma (NSCLC)1
3CompletedSupportive CareAnorexic / Cachexia / Lung Cancers / Tiredness1
3CompletedSupportive CareCancer, Breast1
3CompletedSupportive CareCancer, Breast / Chemotherapy Induced Neutropenia1
3CompletedSupportive CareChemotherapy Induced Neutropenia1
3CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
3CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
3CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Malignant Neoplasm of Stomach / Nausea and Vomiting / Pain1
3CompletedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
3CompletedTreatmentCancer, Breast40
3CompletedTreatmentCancer, Breast / Stage IV Breast Cancer1
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
3CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
3CompletedTreatmentCancers1
3CompletedTreatmentCarcinoma NOS / Non Small Cell Lung1
3CompletedTreatmentHead and Neck Carcinoma2
3CompletedTreatmentHypopharynx Cancer / Laryngeal Cancer1
3CompletedTreatmentIll-defined Sites / Supportive1
3CompletedTreatmentInflammatory carcinoma of the breast1
3CompletedTreatmentInoperable Gastric Cancer1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)18
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small-Cell Lung Cancer Metastatic / Non-Small-Cell Lung Cancer Stage IIIB / Non-Small-Cell Lung Cancer Stage IV1
3CompletedTreatmentLung Cancers5
3CompletedTreatmentMalignant Neoplasm of Female Breast1
3CompletedTreatmentMalignant Neoplasm of Stomach1
3CompletedTreatmentMetastatic Breast Cancer (MBC)2
3CompletedTreatmentMetastatic Cancers / Prostate Cancer1
3CompletedTreatmentMetastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma1
3CompletedTreatmentNeoplasms Metastasis / Prostatic Neoplasms1
3CompletedTreatmentNeoplasms, Breast6
3CompletedTreatmentNeoplasms, Lung2
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
3CompletedTreatmentProstate Cancer7
3CompletedTreatmentProstatic Neoplasms2
3CompletedTreatmentSoft Tissue Sarcoma (STS)1
3CompletedTreatmentSquamous Cell Carcinoma (SCC)1
3CompletedTreatmentStage I Breast Carcinoma1
3CompletedTreatmentStomach Neoplasms1
3Enrolling by InvitationTreatmentCancers1
3Enrolling by InvitationTreatmentMalignant Neoplasm of Stomach1
3Not Yet RecruitingTreatmentHER2 Positive Breast Cancers1
3Not Yet RecruitingTreatmentNasopharyngeal Carcinoma2
3Not Yet RecruitingTreatmentNon-squamous Cell NSCLC1
3RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction / Esophageal Adenocarcinoma (UICC TNM7)1
3RecruitingTreatmentBreast Cancer Model / Cancer, Breast / Effects of Chemotherapy1
3RecruitingTreatmentBreastcancer / Neutropenias1
3RecruitingTreatmentCancer, Breast3
3RecruitingTreatmentCancer, Breast / Metastasis1
3RecruitingTreatmentCervical Cancers1
3RecruitingTreatmentChemoradiotherapy / Enteral Nutrition Therapy / Squamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentChemotherapy Effects / Esophagus Cancer1
3RecruitingTreatmentEsophageal Cancers1
3RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Esophagus / Squamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentEsophagogastric Junction Carcinoma / Oesophageal Carcinoma1
3RecruitingTreatmentGastric Adenocarcinoma1
3RecruitingTreatmentGastric Cancer, Adjuvant Chemotherapy, XO1
3RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3RecruitingTreatmentLocally Advanced Nasopharyngeal Carcinoma1
3RecruitingTreatmentLocally Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
3RecruitingTreatmentMalignant Neoplasm of Stomach1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3RecruitingTreatmentNasopharyngeal Carcinoma3
3RecruitingTreatmentNasopharyngeal Neoplasms1
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentOESOPHAGO-GASTRIC CARCINOMA1
3RecruitingTreatmentOligo-metastatic Stage IV Non-small Cell Lung Cancer / Oligo-metastatic Stage IV Non-small Cell Lung Cancer(NSCLC)1
3RecruitingTreatmentOropharynx Cancers1
3RecruitingTreatmentProstate Cancer Adenocarcinoma Metastatic1
3RecruitingTreatmentProstatic Neoplasms1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer / Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Non-Small-Cell Lung Adenocarcinoma1
3TerminatedTreatmentCancer, Breast3
3TerminatedTreatmentCastrate-resistant Prostate Cancer (CRPC) / Hormone Refractory Prostate Cancer1
3TerminatedTreatmentHead and Neck Carcinoma2
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
3TerminatedTreatmentLung Cancers2
3TerminatedTreatmentMetastatic Head and Neck Cancer / Recurrent Head and Neck Cancer1
3TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
3TerminatedTreatmentProstate Cancer5
3TerminatedTreatmentProstatic Neoplasms2
3TerminatedTreatmentRecurrent Uterine Corpus Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1
3Unknown StatusDiagnosticCancer, Breast1
3Unknown StatusScreeningNeoplasms, Lung1
3Unknown StatusTreatmentAdenocarcinoma of the Prostate1
3Unknown StatusTreatmentAdvanced Prostate Cancer1
3Unknown StatusTreatmentCancer of the Larynx / Cancer of the Nasal Cavity / Cancer of the Oral Cavity / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
3Unknown StatusTreatmentCancer, Breast6
3Unknown StatusTreatmentCancer, Breast / Cardiac Toxicity / Perioperative/Postoperative Complications1
3Unknown StatusTreatmentCancer treatment / Cancer, Breast1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusTreatmentLung Cancers3
3Unknown StatusTreatmentPain / Prostate Cancer1
3Unknown StatusTreatmentProstate Cancer3
3WithdrawnTreatmentAdult Solid Tumor / Cancer, Breast / Head and Neck Carcinoma / Kidney and Urinary Cancer / Male Reproductive Cancer / Thorax and Respiratory Cancer1
4Active Not RecruitingTreatmentCancer, Breast2
4Active Not RecruitingTreatmentNeoplasms, Therapy-Associated1
4CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
4CompletedTreatmentCancer, Breast2
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
4CompletedTreatmentNeoplasms, Head and Neck1
4CompletedTreatmentProstatic Neoplasms1
4CompletedTreatmentSquamous Cell Carcinoma (SCC)1
4RecruitingScreeningLiver Injury, Drug-Induced1
4RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer1
4RecruitingTreatmentAdvanced Lung Squamous Carcinoma1
4RecruitingTreatmentCancer, Breast3
4RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4RecruitingTreatmentNeoplasms, Breast1
4RecruitingTreatmentPatients With Head and Neck Cancer (ORL)1
4TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4WithdrawnTreatmentCancer, Breast1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Chemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Adults / Neurotoxicity / Psychosocial Effects of Cancer and Its Treatment / Tiredness1
Not AvailableActive Not RecruitingNot AvailableMetastatic Cancers / Prostate Cancer1
Not AvailableActive Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
Not AvailableActive Not RecruitingTreatmentLung Cancers1
Not AvailableCompletedNot AvailableAssociations Between Genetic Data and Docetaxel Toxicity / CYP3A Phenotyping / CYP3A5 and MDR1 Genotyping / Docetaxel Toxicity1
Not AvailableCompletedNot AvailableCancer, Breast2
Not AvailableCompletedNot AvailableMalignant Neoplasm of Colon / Metastatic Breast Cancer (MBC) / Metastatic Breast Cancer, Colon Cancer1
Not AvailableCompletedNot AvailableMetastatic Cancers / Prostate Cancer1
Not AvailableCompletedNot AvailableNeoplasms1
Not AvailableCompletedNot AvailableNeoplasms, Ovarian1
Not AvailableCompletedDiagnosticCancer, Breast1
Not AvailableCompletedHealth Services ResearchLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedTreatmentCancer, Breast6
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedTreatmentSquamous Cell Carcinoma of Esophagus1
Not AvailableNot Yet RecruitingNot AvailableMetastatic Castration Resistant Prostate Cancer1
Not AvailableRecruitingNot AvailableMalnutrition / Nasopharyngeal Carcinoma2
Not AvailableRecruitingNot AvailableProstate Cancer2
Not AvailableRecruitingHealth Services ResearchCancer, Breast1
Not AvailableRecruitingTreatmentAdenocarcinomas1
Not AvailableRecruitingTreatmentBreast Cancer Nos Premenopausal1
Not AvailableRecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentDrug-Related Side Effects and Adverse Reactions1
Not AvailableRecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableTerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
Not AvailableTerminatedTreatmentMalignant Neoplasm of Pancreas1
Not AvailableTerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableUnknown StatusNot AvailableHormone Refractory Prostate Cancer1
Not AvailableUnknown StatusNot AvailableProstate Cancer1
Not AvailableUnknown StatusTreatmentCancer, Breast1
Not AvailableUnknown StatusTreatmentProstate Cancer1
Not AvailableUnknown StatusTreatmentStage IA Uterine Sarcoma / Stage IB Uterine Sarcoma / Stage IC Uterine Sarcoma / Stage IIA Uterine Sarcoma / Stage IIB Uterine Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Kit
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous20 mg/mL
Injection, solutionIntravenous80 mg/4mL
Injection, solution, concentrateIntravenous20 mg/mL
Injection, solution, concentrateIntravenous20 mg/2mL
Injection, solution, concentrateIntravenous200 mg/20mL
Injection, solution, concentrateIntravenous40 mg/mL
Injection, solution, concentrateIntravenous80 mg/8mL
SolutionIntravenous20 mg/mL
SolutionIntravenous10 mg
Injection, solution, concentrateIntravenous120 mg/6ml
Injection, solution, concentrateIntravenous160 mg/8ml
Injection, solution, concentrateIntravenous180 mg/9ml
Injection, solution, concentrateIntravenous20 mg/1ml
Injection, solution, concentrateIntravenous200 mg/10ml
Injection, solution, concentrateIntravenous80 mg/4ml
InjectionIntravenous20 mg/mL
Injection, solution, concentrateIntravenous20 mg
Injection, solution, concentrateIntravenous80 mg
Kit; solutionIntravenous20 mg
Kit; solutionIntravenous80 mg
SolutionIntravenous160 mg
Injection, solution, concentrateIntravenous140 mg/7ml
Injection, solution, concentrateIntravenous20 mg/0.5ml
Injection, solution, concentrateIntravenous80 mg/2ml
SolutionIntravenous20 mg
SolutionIntravenous80 mg
Prices
Unit descriptionCostUnit
Taxotere 20 mg/0.5 ml vial477.37USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5438072No1994-05-222014-05-22Us
US4814470No1993-05-142010-05-14Us
CA2150576No2005-06-212013-11-26Canada
CA2149055No2003-01-072013-11-08Canada
US8940786No2013-09-302033-09-30Us
US9308195No2013-09-302033-09-30Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)232 °CPhysProp
water solubilityInsoluble FDA label
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP2.59ALOGPS
logP2.92ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area224.45 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity203.9 m3·mol-1ChemAxon
Polarizability82.06 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9743
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8252
P-glycoprotein substrateSubstrate0.8259
P-glycoprotein inhibitor IInhibitor0.644
P-glycoprotein inhibitor IINon-inhibitor0.5139
Renal organic cation transporterNon-inhibitor0.9393
CYP450 2C9 substrateNon-substrate0.816
CYP450 2D6 substrateNon-substrate0.8828
CYP450 3A4 substrateSubstrate0.7119
CYP450 1A2 substrateNon-inhibitor0.8299
CYP450 2C9 inhibitorNon-inhibitor0.8737
CYP450 2D6 inhibitorNon-inhibitor0.8972
CYP450 2C19 inhibitorNon-inhibitor0.8421
CYP450 3A4 inhibitorNon-inhibitor0.7324
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8776
Ames testNon AMES toxic0.8382
CarcinogenicityNon-carcinogens0.9133
BiodegradationNot ready biodegradable0.9934
Rat acute toxicity2.5741 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist: 2(3->20)-abeotaxane, 3,11-cyclotaxane, 11(15->1),11(10->9)-abeotaxane, 3,8-seco-taxane, and 11(15->1)-abeotaxane, among others. More complex skeletons have been found recently, which include the taxane-derived [3.3.3] propellane ring system.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Diterpenoids
Direct Parent
Taxanes and derivatives
Alternative Parents
Benzoic acid esters / Tricarboxylic acids and derivatives / Benzoyl derivatives / Fatty acid esters / Monosaccharides / Tertiary alcohols / Carbamate esters / Secondary alcohols / Oxetanes / Carboxylic acid esters
show 10 more
Substituents
Taxane diterpenoid / Benzoate ester / Benzoic acid or derivatives / Tricarboxylic acid or derivatives / Benzoyl / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Monosaccharide / Benzenoid
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tetracyclic diterpenoid (CHEBI:4672)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name
TUBB1
Uniprot ID
Q9H4B7
Uniprot Name
Tubulin beta-1 chain
Molecular Weight
50326.56 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985]
  2. Matesanz R, Barasoain I, Yang CG, Wang L, Li X, de Ines C, Coderch C, Gago F, Barbero JJ, Andreu JM, Fang WS, Diaz JF: Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chem Biol. 2008 Jun;15(6):573-85. doi: 10.1016/j.chembiol.2008.05.008. [PubMed:18559268]
  3. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E: The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5312-6. Epub 2001 Apr 17. [PubMed:11309480]
  4. Belani CP, Eckardt J: Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 2004 Dec;46 Suppl 2:S3-11. [PubMed:15698529]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appea...
Gene Name
BCL2
Uniprot ID
P10415
Uniprot Name
Apoptosis regulator Bcl-2
Molecular Weight
26265.66 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985]
  2. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004 Aug;15(8):1274-83. [PubMed:15277270]
  3. Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K: Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep. 2005 Feb;13(2):259-64. [PubMed:15643508]
  4. Petrylak DP: Chemotherapy for androgen-independent prostate cancer. World J Urol. 2005 Feb;23(1):10-3. Epub 2005 Feb 1. [PubMed:15685445]
  5. Miyoshi Y, Uemura H, Kubota Y: [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho. 2005 Feb;63(2):298-302. [PubMed:15714982]
  6. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA: Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007 Sep 15;110(6):1248-54. [PubMed:17674353]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Structural molecule activity
Specific Function
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.
Gene Name
MAP2
Uniprot ID
P11137
Uniprot Name
Microtubule-associated protein 2
Molecular Weight
199524.51 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Structural molecule activity
Specific Function
Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
Gene Name
MAP4
Uniprot ID
P27816
Uniprot Name
Microtubule-associated protein 4
Molecular Weight
121003.805 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Structural constituent of cytoskeleton
Specific Function
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neu...
Gene Name
MAPT
Uniprot ID
P10636
Uniprot Name
Microtubule-associated protein tau
Molecular Weight
78927.025 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP: HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004 Oct 15;64(20):7426-31. [PubMed:15492266]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455]
  2. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K: Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res. 1999 Dec;90(12):1380-6. [PubMed:10665657]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A: Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28. [PubMed:18509327]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8. [PubMed:15901346]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33